CMS to overhaul Medicare comparison tools

CMS is planning to launch a simplified comparison tool for Medicare beneficiaries to find care.

The plan will tackle the differences between current available tools. For example, each of the eight available comparison tools for Medicare beneficiaries, such as Hospital or Nursing Home Compare, use different interfaces and function independently. These tools are widely used, but their varying interfaces make them “challenging to navigate,” according to CMS.

CMS will combine and standardize the eight existing Compare tools so users can access the information through a single portal with simplified navigation. The new version will be called Medicare Care Compare. The current tools compare quality and patient measures through star ratings.

“In the new, unified experience, patients will be able to easily find the information that is most important to help make health care decisions, like getting quality data by the type of health care provider,” CMS Administrator Seema Verma wrote in a blog post.

In addition, the agency will launch the Provider Data Catalog for Medicare researchers and stakeholders to search datasets via an Application Programming Interface.

Both tools are scheduled to be launched in spring 2020, with the agency giving a transition period when the old comparison tools will still be available.

“Even though we’re making these enhancements, it doesn’t change our public reporting requirements, and we will continue to meet every reporting mandate,” Verma wrote.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.